Furthermore, the uptake of naringenin-loaded albumin-coated liposomes by activated HSCs was 1.5 times higher than that of naringenin-loaded liposomes with no albumin coating, suggesting that naringenin-loaded albumin-coated liposomes specifically increased the targeting of activated HSCs via albumin and SPARC-dependent pathways in treating liver fibrosis. This evidence concerns the gene ALB and Hepatic fibrosis.